Skip Navigation

Cardiovascular Research 2004 64(2):192-194; doi:10.1016/j.cardiores.2004.07.008
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kojda, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kojda, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?

Georg Kojda*

Institut für Pharmakologie und Klinische Pharmakologie, Medizinische Einrichtungen, Heinrich-Heine-Universität, Moorenstr. 5, 40225 Düsseldorf, Germany

* Tel.: +49 211 81 12518; fax: +49 211 81 14781. Email address: kojda@uni-duesseldorf.de

Received 13 July 2004; accepted 15 July 2004

The first 10% of the full text of this article appears below.

See article by Mehta et al. [14] (pages 243–249) in this issue.


   1. Introduction
 
Acetylsalicylic acid (aspirin) is an important drug in cardiovascular medicine. The evaluation in large clinical trials of its efficacy in preventing acute coronary events began about 20 years ago [1,2] and is still ongoing. An important consequence of this is the worldwide recommendation to use low-dose aspirin for primary and secondary prevention of myocardial infarction and for treatment of unstable angina and non-ST-segment myocardial infarction [3,4]. Likewise, aspirin can be used safely for the prevention of vascular events in the cerebral and peripheral circulation, although higher doses might be required . . . [Full Text of this Article]


   2. Antiplatelet activity
 

   3. Vascular effects
 

   4. Vascular molecular mechanisms
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?